The position of combined treatment in the context of updated ESC/EAS recommendations for the management of dyslipidemias

Czech version

Authors: Branislav Vohnout ^1,2
Authors‘ workplace: Ústav výživy, Fakulta ošetrovateľstva a zdravotníckych odborných štúdií a Koordinačné centrum pre familiárne hyperlipoproteinémie, SZU, Bratislava ¹; Diabetologická ambulancia, Diabeda s. r. o., Bratislava ²
Published in: AtheroRev 2026; 11(1): 7-9
Category: Guidelines

Overview

The update of the 2019 ESC/EAS guidelines for the management of dyslipidemias, published in the summer of 2025, brings several significant changes and new recommendations. From the perspective of LDL-C-lowering therapy, new drugs and combinations for further LDL-C reduction were added based on new data and emphasized the need for early combination therapy in patients with ACS.

Keywords:

dyslipidemia – management – guidelines

Sources

1. Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis 2019; 290 : 140–205. Dostupné z DOI:<http://dx.doi.org/10.1016/j.atherosclerosis.2019.08.014>. Erratum in:Atherosclerosis 2020; 292 : 160–162. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2019.11.020>. Corrigendum in: Atherosclerosis 2020; 294 : 80–82. Dostupné z DOI:<http://dx.doi.org/10.1016/j.atherosclerosis.2019.12.004>.
2. Mach F, Koskinas KC, Roeters van Lennep JE et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis 2025; 409 : 120479. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2025.120479>.
3. Visseren FL, Mach F, Smulders YM et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 42(34):3227–3237. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehab484>. Erratum in: Eur Heart J 2022; 43(42): 4468. Dostupné z DOI:<http://dx.doi.org/10.1093/eurheartj/ehac458>.